We are live on ! Find out more
BNTX icon

BioNTech

252 hedge funds and large institutions have $4.01B invested in BioNTech in 2023 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 71 increasing their positions, 77 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 31

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

0.01% less ownership

Funds ownership: 15.42%15.42% (-0.01%)

0% less funds holding

Funds holding: 253252 (-1)

1% less call options, than puts

Call options by funds: $230M | Put options by funds: $232M

1% less capital invested

Capital invested by funds: $4.05B → $4.01B (-$39.4M)

8% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 77

Holders
252
Holders Change
-1
Holders Change %
-0.4%
% of All Funds
4%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
33
Increased
71
Reduced
77
Closed
31
Calls
$230M
Puts
$232M
Net Calls
-$1.4M
Net Calls Change
+$90.2M

BNTX Hedge Fund Activity: Q3 2023 in Review

252 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q3 2023, worth a combined $4.01B — down 0.97% from $4.05B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BNTX positions and 31 closed out — a net gain of 2 holders — while 71 added to existing stakes and 77 trimmed.

The largest buyer was Baillie Gifford & Co, adding an estimated $127M. The largest seller was Artisan Partners, cutting an estimated $143M.

  • 252 institutional investors held BioNTech (BNTX) as of Q3 2023, down from 253 in Q2 2023.
  • Funds reported $4.01B of BioNTech stock for Q3 2023, down 0.97% quarter-over-quarter.
  • 33 funds opened new BioNTech positions in Q3 2023 and 31 closed out, a net change of +2 holders.
  • The largest BioNTech buyer in Q3 2023 was Baillie Gifford & Co, an estimated $127M added.
  • The largest BioNTech seller in Q3 2023 was Artisan Partners, an estimated $143M sold.

Based on aggregated 13F filings for Q3 2023.